Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive…
- Avacc 3 has significant advantages over existing whooping cough vaccines
- Second major OMV platform licensing agreement with pharmaceutical company
- Over 24 million cases of whooping cough per year world-wide